Impact of relative dose intensity on efficacy of enfortumab vedotin monotherapy in platinum and ICI resistant metastatic urothelial carcinoma: A multi-institutional real-world analysis.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.5_suppl.728
Abstract: 728 Background: The treatment paradigm for metastatic or locally advanced urothelial carcinoma (mUC) has shifted towards combination therapies with Enfortumab Vedotin (EV) and Pembrolizumab. Understanding EV's characteristics is crucial for optimizing treatment. The EV-101 trial… read more here.
Keywords: dose; relative dose; real world; brrdi ... See more keywords